Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Pipeline Review, H1 2016 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome)) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Overview
  3. Therapeutics Development
  4. Pipeline Products for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Overview
  5. Pipeline Products for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Comparative Analysis
  6. Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Therapeutics under Development by Companies
  7. Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Therapeutics under Investigation by Universities/Institutes
  8. Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Products under Development by Companies
  13. Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Products under Investigation by Universities/Institutes
  14. Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) - Companies Involved in Therapeutics Development
  • AngioChem Inc.
  • ArmaGen Inc.
  • Athersys, Inc.
  • Bioasis Technologies Inc.
  • Eloxx Pharmaceuticals, Ltd.
  • Inventiva
  • OPKO Health, Inc.
  • PTC Therapeutics, Inc.
  • RegenxBio Inc.
  • Sangamo BioSciences, Inc.

For more information visit http://www.researchandmarkets.com/research/qwwspn/mucopolysaccharido

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders Drugs